PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of cureusLink to Publisher's site
 
Cureus. 2017 January; 9(1): e1004.
PMCID: PMC5332167

Fecal Myeloperoxidase as a Biomarker for Inflammatory Bowel Disease

Monitoring Editor: Alexander Muacevic and John R Adler

Abstract

Inflammatory bowel disease (IBD) is a chronic condition involving the inflammation of the colon and small intestine. IBD affects as many as 1.4 million people in the U.S. alone and costs the health care industry over $1.7 billion annually. Managing IBD normally requires invasive and often discomforting diagnostic tests. In an effort to alleviate the painful and costly nature of traditional diagnosis, there has been increasing research initiative focused on noninvasive biomarkers. PubMed, provided by the United States National Library of Medicine (NLM) at the National Institutes of Health, was utilized with the following search terms: 1) myeloperoxidase (MPO) 2), inflammatory bowel disease (IBD), and 3) neutrophils. The following terms were used interchangeably with search terms 1-3: 4) costs, 5) biomarkers, 6) review, and 7) etiology. In the context of IBD, myeloperoxidase (MPO), a lysosomal protein found in neutrophils, may serve as a viable biomarker for assessing disease status. Several studies demonstrated increased levels of neutrophils in patients with active IBD. Furthermore, studies have found significantly higher levels of MPO in patients with active IBD compared to patients without IBD as well as patients with inactive IBD. MPO is also expressed in higher concentrations in patients with more severe forms of IBD. When measuring treatment efficacy, MPO levels are indicative of the quality of response. MPO may serve as an important diagnostic and prognostic tool in assessing IBD status. 

Keywords: myeloperoxidase, biomarker, ulcerative colitis, crohn’s disease, inflammatory bowel disease

Introduction and background

Despite the progress that has been made in biomarker detection technology, challenges remain for improved screening, detection, and treatment of many intractable diseases. In the biomarker research continuum, important steps include the identification of reproducible patterns of disease and response to therapy; capacity to distinguish between health and disease or differentiating diseases when they have overlapping symptoms; collection of specimens, often minute in nature; and platforms that can accurately measure single or multiple markers with rapid, reliable, and reproducible automation technology. All of these challenges are inherent to many diseases, including inflammatory bowel disease (IBD).

Inflammatory bowel disease is a chronic disease of intestinal inflammation that can have serious morbidity and mortality as well as a significant economic burden with annual estimates of total expenditures at $2.8 billion in the United States alone [1]. Frequently, IBD refers to ulcerative colitis (UC) and Crohn’s disease (CD), two of the most prevalent IBDs. Both diseases require extensive diagnostic workup and treatment monitoring, which can be discomforting to the patient. The use of noninvasive diagnostic biomarkers to monitor treatment efficacy and assist in clinical decision-making is beneficial to both the clinician and patient. Many biomarkers have been investigated for clinical usefulness in IBD, including lactoferrin, calprotectin, and myeloperoxidase (MPO). This article reviews the use of MPO as a fecal biomarker in patients with IBD.

PubMed, provided by the United States National Library of Medicine (NLM) at the National Institutes of Health, was utilized with the following search terms: 1) myeloperoxidase (MPO), 2) inflammatory bowel disease (IBD), and 3) neutrophils. The following terms were used interchangeably with search terms 1-3: 4) costs, 5) biomarkers, 6) review, and 7) etiology. References were selected to better understand the role of biomarkers, specifically MPO, in IBD (Table (Table1)1) [2-15].

Table 1
Selected References on the Role of Fecal Myeloperoxidase (MPO) as a Biomarker for Inflammatory Bowel Disease

Review

Myeloperoxidase

Myeloperoxidase is a lysosomal protein that is released into the phagosome of neutrophils during the degranulation process. There, it reacts with hydrogen peroxide and a halide to form hypochlorous acid or with tyrosine to form tyrosyl radicals. These products are highly cytotoxic and can be released from the cell to destroy foreign microorganisms. However, these toxic agents can also damage normal tissue and contribute to inflammation [7]. Myeloperoxidase is often overexpressed in numerous inflammatory diseases, including IBD [16-17]. As a result, MPO has the potential to serve as a viable, noninvasive fecal biomarker for assessing IBD status.

Neutrophil and IBD studies   

Calprotectin, lactoferrin, and MPO are all associated with inflammation and are derived from neutrophils. Calprotectin is found within the cytosol of neutrophils. Studies have successfully shown elevated levels of calprotectin in patients with IBD and that fecal calprotectin accurately predicts relapses [18]. Lactoferrin is a glycoprotein found in the secondary granules of neutrophils and is resistant to proteolysis in feces [19]. Studies have found it to be both sensitive and accurate in measuring IBD activity [20]. Both calprotectin and lactoferrin are documented biomarkers for monitoring and helping diagnose IBD.

To investigate the relationship between circulating neutrophils and IBD, McCarthy, et al. compared inactivated and activated neutrophils in patients with active CD and UC, inactive CD and UC, and healthy patients. The authors found increased levels of activated circulating neutrophils in active CD and active UC subjects compared to healthy and inactive CD and UC patients [21]. To examine the cellular intricacies behind the characteristic transepithelial neutrophil migration, Kucharzik, et al. studied the tight junction and adherens junction expression levels relative to neutrophil infiltration in patients with IBD. Immunofluorescence data revealed a severe down-regulation of the tight junction protein occludin. The authors concluded that reduced expression of occludin might be involved in the enhanced permeability of neutrophils seen in IBD [22]. To explore the prolonged persistence and accumulation of neutrophils in IBD, Ina, et al. studied the effects of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage CSF (GM-CSF) on neutrophil apoptosis in IBD patients. The authors discovered that patients with active IBD have elevated levels of G-CSF and GM-CSF activity compared to the controls. Furthermore, neutrophils exposed to both factors exhibited concentration-dependent inhibition of apoptosis. The authors suggest that neutrophil apoptosis is delayed due to factors G-CSF and GM-CSF, which may explain why neutrophils accumulate in the tissues of IBD patients [23]. The aforementioned studies describe the relationship between neutrophils and IBD as well as possible mechanisms underlying the nature of neutrophils in IBD.

MPO and IBD studies

Saiki performed one of the more influential studies concerning the relationship between MPO and IBD. The author measured MPO levels in stool extracts of 33 patients with UC, 32 patients with CD, 9 inflammatory disease control patients, and 15 healthy patients. The author found decreased levels of MPO in the healthy patient population as well as the patients with inactive IBD when compared to patients with active IBD. In fact, there was a statistically significant elevation in MPO levels for active IBD compared to inactive and healthy controls. A paired analysis showed reduced MPO levels after the disease was aggravated and resolved. Saiki further found a linkage between MPO, alternative disease parameters (such as leukocyte counts), and the endoscopic grade of inflammation [3].

Other studies have also been conducted regarding MPO and IBD. Peterson, et al. evaluated different biomarkers in 28 patients with active UC using fecal and serum samples. The authors found elevated fecal MPO levels in all 28 UC patients irrespective of the disease severity. Furthermore, the authors found reduced levels of fecal MPO after four weeks of treatment in 20 of the 28 patients [24]. To further study the role of MPO in assessing IBD activity and response to therapy, Masoodi, et al. examined the fecal MPO levels in 55 patients with UC and 54 age-matched healthy patients. The authors reported elevated MPO levels in the UC patients compared to the control patients. Of the 55 patients with UC, the authors also reported significantly higher fecal MPO levels in the subjects with endoscopically more severe disease compared to those with milder cases of UC [2]. To examine the use of monitoring MPO levels in active IBD, Ping, et al. determined bowel histological scores of 15 active IBD patients, 15 inactive IBD patients, and 12 control patients. The authors determined there was elevated bowel mucosal MPO activity in active and inactive IBD patients compared to control patients. Between patients with active and inactive IBD, bowel mucosal MPO activity was increased in patients with active IBD [25]. These studies suggest and promote measuring MPO levels to assess IBD activity and response to therapy.

Translational applicability

Several studies have explored the potential use of MPO in clinical practice. Wagner, et al. investigated fecal samples of MPO as an indicator of treatment efficacy for 38 patients with IBD before and after four and eight weeks of treatment. The authors found that increased levels of MPO could indicate an incomplete response to treatment while decreased levels of MPO could indicate a full response to treatment [14]. To examine MPO’s ability to serve as a disease activity marker in IBD, Peterson, et al. measured MPO levels in 44 healthy patients and 18 IBD patients and found relatively higher MPO levels in IBD patients compared to healthy patients. The authors also observed a high discriminative capability for MPO between healthy and IBD patients [12]. These studies argue for MPO as a valuable biomarker for diagnosing and evaluating treatment efficacy of IBD.

There is an obvious need for a noninvasive, reliable, inexpensive, and quick method to assess as well as analyze IBD status and response to treatment in the clinical environment [26]. Currently, the gold standard for monitoring and managing gastrointestinal inflammation is an endoscopy with muscle biopsy. It is supplemented with laboratory tests and radiologic exams [27]. The use of multiple procedures highlights the difficulty in properly checking IBD activity. Recently, the advent of biomarkers has shown promise in resolving such issues. Myeloperoxidase has been studied for IBD diagnostic potential, disease reoccurrence rates, and treatment efficacy [28]. Myeloperoxidase seems to be a prospective biomarker and may serve as a critical tool in sensing and managing IBD. Current costs of detecting and monitoring IBD are approximated to over $500,000 per quality-adjusted life years. These costs are predominately due to performing endoscopy and colonoscopy procedures. Utilizing biomarkers may lower these costs by as much as 31% and have the potential to save patients both time and inconvenience [29]. In fact, a recent study regarding the use of MPO as a biomarker for inflammation in ischemic heart disease suggested that, with new commercial methods, it is feasible to measure MPO at a low cost and high volume [30]. There is a practical application in measuring MPO levels in clinical environments to assess IBD status.

Discussion

The diagnosis and management of IBD entails lengthy, costly, and invasive procedures. It would be beneficial to monitor IBD using an inexpensive, consistent, and rapid test. The realm of biomarkers provides a promising avenue to reliably monitor IBD activity. The logic behind fecal biomarkers is that they are in direct contact with the intestine and should contain markers specific to IBD. The presence of these biomarkers indicate the onset and severity of IBD [15]. One characteristic feature of IBD is the infiltration of neutrophils into the gastrointestinal tract wall as well as expulsion of neutrophil proteins into the bowel lumen. With this in mind, MPO, a lysosomal protein found within neutrophils, is thought to be a potential fecal biomarker in evaluating IBD. Several preliminary studies have explored and validate its use as a fecal biomarker in assessing bowel disease activity. Both Masoodi, et al. and Ping, et al. found elevated MPO levels in patients with IBD compared to healthy patients [2, 25]. Furthermore, their studies revealed that fecal MPO levels are higher in patients with more severe forms of IBD. Wagner, et al. and Peterson, et al. examined the relationship between fecal MPO levels and IBD treatment [12, 14]. These authors showed reduced levels of fecal MPO after treatment and that fecal MPO levels indicate the degree of responsiveness to IBD treatment. 

Conclusions

The future of MPO in evaluating IBD is promising. Not only does it hold promise to be cost-effective to measure MPO levels to assess IBD status, it is also safer and more convenient for the patient as well as the clinician. The possibility of utilizing a biomarker like MPO is rational given its involvement in IBD. Further large population studies need to be done to better understand and validate MPO's diagnostic and prognostic value in assessing IBD. However, due to its specificity, simplicity, non-invasive, and likely inexpensive nature, MPO may serve as an important tool for evaluating patients with IBD.

Notes

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

Footnotes

The authors have declared that no competing interests exist.

References

1. The economic burden of inflammatory bowel disease: clear problem, unclear solution. Stone CD. Dig Dis Sci. 2012;57:3042–3044. [PubMed]
2. Evaluation of fecal myeloperoxidase as a biomarker of disease activity and severity in ulcerative colitis. Masoodi I, Kochhar R, Dutta U, Vaishnavi C, Prasad KK, Vaiphei K, Hussain S, Singh K. Dig Dis Sci. 2012;57:1336–1340. [PubMed]
3. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Saiki T. https://www.jstage.jst.go.jp/article/kurumemedj1954/45/1/45_1_69/_article/-char/ja/ Kurume Med J. 1998;45:69–73. [PubMed]
4. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase) Merlie JP, Fagan D, Mudd J, Needleman P. http://www.jbc.org/content/263/8/3550.short. J Biol Chem. 1988;263:3550–3553. [PubMed]
5. Human myeloperoxidase and thyroid peroxidase, two enzymes with separate and distinct physiological functions, are evolutionarily related members of the same gene family. Kimura S, Ikeda-Saito M. Proteins. 1988;3:113–120. [PubMed]
6. Primary structure of bovine lactoperoxidase, a fourth member of a mammalian heme peroxidase family. Cals MM, Mailliart P, Brignon G, Anglade P, Dumas BR. Eur J Biochem. 1991;198:733–739. [PubMed]
7. Myeloperoxidase: friend and foe. Klebanoff SJ. J Leukoc Biol. 2005;77:598–625. [PubMed]
8. Biomarkers in the management of ulcerative colitis: a brief review. German medical science. Masoodi I, Tijjani BM, Wani H, Hassan NS, Khan AB, Hussain S. GMS e-journal. 2011;9:3. [PMC free article] [PubMed]
9. A technique for segmental rectal and colonic perfusion in humans. Raab Y, Hallgren R, Knutson L, Krog M, Gerdin B. https://www.ncbi.nlm.nih.gov/pubmed/1415103. Am J Gastroenterol. 1992;87:1453–1459. [PubMed]
10. Properties, functions, and secretion of human myeloperoxidase. Arnhold J. Biochemistry (Mosc) 2004;69:4–9. [PubMed]
11. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. Sangfelt P, Carlson M, Thorn M, Loof L, Raab Y. Am J Gastroenterol. 2001;96:1085–1090. [PubMed]
12. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. Am J Gastroenterol. 2002;97:1755–1762. [PubMed]
13. Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. Lettesjö H, Hansson T, Peterson C, Ung KA, Ringstrom G, Abrahamsson H, Simren M. Scand J Gastroenterol. 2006;41:54–59. [PubMed]
14. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. http://www.wjgnet.com/1007-9327/full/v14/i36/5584.htm. World J Gastroenterol. 2008;14:5584–5589. [PMC free article] [PubMed]
15. Review of fecal biomarkers in inflammatory bowel disease. Sutherland AD, Gearry RB, Frizelle FA. Dis Colon Rectum. 2008;51:1283–1291. [PubMed]
16. Myeloperoxidase and its contributory role in inflammatory vascular disease. Lau D, Baldus S. Pharmacol Ther. 2006;111:16–26. [PubMed]
17. Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. Pattison DI, Davies MJ. Curr Med Chem. 2006;13:3271–3290. [PubMed]
18. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Konikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12:524–534. [PubMed]
19. Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update. Turkay C, Kasapoglu B. Clinics (Sao Paulo) 2010;65:221–231. [PMC free article] [PubMed]
20. Relationship between fecal lactoferrin and inflammatory bowel disease. Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Scand J Gastroenterol. 2007;42:1440–1444. [PubMed]
21. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. McCarthy DA, Rampton DS, Liu YC. Clin Exp Immunol. 1991;86:489–493. [PubMed]
22. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A. Am J Pathol. 2001;159:2001–2009. [PubMed]
23. Increased mucosal production of granulocyte colony-stimulating factor is related to a delay in neutrophil apoptosis in Inflammatory Bowel disease. Ina K, Kusugami K, Hosokawa T, Imada A, Shimizu T, Yamaguchi T, Ohsuga M, Kyokane K, Sakai T, Nishio Y, Yokoyama Y, Ando T. J Gastroenterol Hepatol. 1999;14:46–53. [PubMed]
24. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Peterson CG, Sangfelt P, Wagner M, Hansson T, Lettesjo H, Carlson M. Scand J Clin Lab Invest. 2007;67:810–820. [PubMed]
25. Clinical importance of myeloperoxidase (MPO) monitoring in activity of inflammatory bowel disease. Ping X, Dongsheng X, Jiang C, Nonghua L, Wang C. http://en.cnki.com.cn/Article_en/CJFDTOTAL-LCSY200612012.htm Practical Clinical Medicine. 2006;7:34–37.
26. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Kristjansson G, Venge P, Wanders A, Loof L, Hallgren R. Gut. 2004;53:1806–1812. [PMC free article] [PubMed]
27. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Standards of Practice Committee, Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV, Faigel DO, Gan SI, Hirota WK, Lichtenstein D, Qureshi WA, Rajan E, Zuckerman MJ, VanGuilder T, Fanelli RD. Gastrointest Endosc. 2006;63:558–565. [PubMed]
28. Laboratory markers in IBD: useful, magic, or unnecessary toys? Vermeire S, Van Assche G, Rutgeerts P. Gut. 2006;55:426–431. [PMC free article] [PubMed]
29. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Park KT, Bass D. Inflamm Bowel Dis. 2011;17:1603–1609. [PubMed]
30. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Loria V, Dato I, Graziani F, Biasucci LM. Mediators Inflamm. 2008;2008:135625. [PMC free article] [PubMed]

Articles from Cureus are provided here courtesy of Cureus Inc.